CD21 positive B cell: A novel target for treatment of multiple sclerosis

Citations of this article
Mendeley users who have this article in their library.


Etiologic-based therapy is an ideal pharmacological option to treat or prevent diseases. There is no known etiology for multiple sclerosis (MS); however, environmental risk factors have been suggested to predispose genetically susceptible people to be affected by the disease. One of these risk factors is infection with Epstein-Barr virus (EBV). Eradication of this virus has not been effective in modulation of MS, probably due to being inhabitant in the CD21 (EBV receptor) positive B cells. To eradicate this virus, targeting CD21 on these EBV-infected B cells is hypothesized here. A sequential study plan to test this hypothesis has been suggested too. This study might eventually suggest an effective immunopharmacological strategy to treat MS. Moreover, testing this strategy will help in better clarification of the role of EBV in MS disease triggering and predisposition. © 2013 Elsevier Ltd.




Farjam, M., Ebrahimpour, A., & Fakhraei, B. (2013). CD21 positive B cell: A novel target for treatment of multiple sclerosis. Medical Hypotheses, 80(5), 556–557.

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free